Teva’s $40.5 billion deal for the generic drug business of Allergan was approved after they agreed to sell some operations to ease antitrust concerns.
Nasdaq’s $1.1 billion deal with Deutsche Börse for an options exchange operator comes as even bigger takeovers loom.
Market speculation that Burberry might be the subject of a takeover bid sent the luxury fashion brand’s shares higher on Tuesday.
Both companies are struggling with volatile iron ore prices driven by expectations over China’s economic growth and subsequent steel demand.
The stock is not cheap, costs are already lean and it’s not clear that a new owner could do much to halt slowing sales.